This C5 inhibitor has been evaluated for paroxysmal nocturnal hemoglobinuria (PNH), CD55-deficient protein-losing enteropathy, and CHAPLE disease [37,38]. This evidence concerns the gene C5 and Protein-losing enteropathy.